Part 7F - Further Information7F.01 The purpose(s) for which the...

Part 7F - Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
Proceeds from the Placement will support the continuation of the Company¿s drug development pipeline, including
CannEpil® and CimetrA® in the US and EU markets.


Reading over the last FOUR Years and more of this company and previously under the OLD Company name -- it would appear that the
Funding Creativity mixed with --- Possible deals , partners, developments and products -- even with moving to UK and slight change of Management --- seems the ingenious ways of getting funding from share holders -- has not diminished as an art form..


Alway DYOR